Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature

Khaldi, Slim; Kornreich, Charles; Choubani, Z.; Gourévitch, Raphaël

doi:10.1016/j.encep.2007.11.007

Cited by 46 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patient has to be advised to drink sufficient amounts of liquids (water and alcohol-free beverages) to keep the body hydrated, to control body temperature, and to ensure proper kidney function. Environmental therapy has a very important role here, since patients should be under observation with respect to their fluid intake even when the patient is on an atypical antipsychotic therapy regime 23. Overhydration (water intoxication) has also been blamed for causing NMS,116 so a balanced water intake is a pivotal factor for both optimal metabolism and the pharmacology of the antipsychotic agent(s) the patient is using, and to maintain normal renal function.…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

“…The incidence of NMS is ~0.2%–3.23% 14. The reported numbers are probably low because physicians and psychiatrists have become aware of the serious side effects that neuroleptics can cause, even the most recently designed ones 23,29…”

Section: Introductionmentioning

confidence: 99%

“…Unfortunately, it was found that these new agents were also capable of causing this syndrome. For example, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone have been criticized for being causative agents 23. Actually, the potent nonselective dopamine receptor (D) antagonist neuroleptics, such as haloperidol (a butyrophenone), promethazine, and chlorpromazine (phenothiazines) are well-known causative factors behind this secondary drug effect 38.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Neuroleptic malignant syndrome: an easily overlooked neurologic emergency

Oruch¹,

Pryme²,

Engelsen³

et al. 2017

NDT

View full text Add to dashboard Cite

Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. It is characterized by distinctive clinical features including a change in mental status, generalized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated properly. Mortality and morbidity attributed to this syndrome have recently declined markedly due to greater awareness, earlier diagnosis, and intensive care intervention. In most cases, the syndrome occurs as a result of a rapid increase in a dose of neuroleptic, especially one of the long-acting ones. Pathophysiology behind this syndrome is attributed to a dopamine receptor blockade inside the neurons rendered by the offending drug and excessive calcium release from the sarcoplasmic reticulum of skeletal myocytes. Laboratory tests, although not diagnostic, may assist in assessing the severity of the syndrome and also the consequent complications. The syndrome has been described in all age groups and occurs more in males than in females. Genetics appears to be central regarding the etiology of the syndrome. Stopping the use of the offending agent, cold intravenous fluids, and removal of the causative agent and its possible active metabolites is the cornerstone of treatment. Periodic observation of psychotic patients recently started on antipsychotic medications, especially those being treated with depot preparations, may aid to an early diagnosis of the syndrome and lead to early treatment.

show abstract

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroleptic malignant syndrome: an easily overlooked neurologic emergency

Oruch¹,

Pryme²,

Engelsen³

et al. 2017

NDT

View full text Add to dashboard Cite

show abstract

“…NMS is commonly encountered by the first-generation antipsychotics. It is uncommon with atypical antipsychotics[1] though cases have been reported with drugs such as olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride, quetiapine, and clozapine. [2] Here, we report a case of NMS induced by olanzapine therapy in a young male having acute and transient psychotic disorder, thereby drawing attention to occurring this fatal adverse event with the use of atypical antipsychotic olanzapine.…”

Section: Introductionmentioning

confidence: 99%

Olanzapine-induced Neuroleptic Malignant Syndrome

Saha

Chakraborty

Layek

et al. 2017

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Neuroleptic malignant syndrome (NMS) is a life-threatening adverse effect usually seen with typical antipsychotic drugs. Rarely, NMS can occur with atypical antipsychotics also. A 19-year-old male diagnosed as a case of acute and transient psychotic disorder developed NMS, following the treatment with an atypical antipsychotic, olanzapine 20 mg/day. The patient was diagnosed NMS, an offending agent olanzapine was immediately withdrawn, and prompt treatment by maintaining hydration and giving bromocriptine produced recovery.

show abstract

“…[345] The following case report draws attention to the development of NMS on Olanzapine, and management of manic episode in a patient with high propensity to NMS.…”

mentioning

confidence: 99%

Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution?

et al. 2013

View full text Add to dashboard Cite

Neuroleptic Malignant Syndrome (NMS) is a rare, severe and life threatening condition induced by antipsychotic medications. It is commonly encountered with the use of first generation antipsychotics, however cases of NMS have been reported with the use of second generation antipsychotics like Olanzapine, Risperidone, Paliperidone, Aripiprazole, Ziprasidone, Amisulpride, Quetiapine and Clozapine, though the incidence of such reports is rare. Due to decreased use of first generation antipsychotics, NMS is reported less frequently now a days. In this case report- we highlight the management issues of a patient suffering from bipolar affective disorder, who had developed NMS following intramuscular injection of haloperidol, which was withdrawn and olanzapine was given later on. The patient had again developed NMS with olanzapine. Finally the patient was managed with modified electroconvulsive therapy and discharged on Lithium carbonate and Quetiapine.

show abstract

Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature

Cited by 46 publications

References 41 publications

Neuroleptic malignant syndrome: an easily overlooked neurologic emergency

Neuroleptic malignant syndrome: an easily overlooked neurologic emergency

Olanzapine-induced Neuroleptic Malignant Syndrome

Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution?

Contact Info

Product

Resources

About